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Abstract
Background: Endovascular repair of aortic aneurysms (EVAR) is obtained through the positioning of an aortic
stent-graft, which excludes the aneurysmatic dilation. Type I endoleak is the most common complication, and it is
caused by an incompetent proximal or distal attachment site, causing the separation between the stent-graft and
the native arterial wall, and in turn creating direct communication between the aneurysm sac and the systemic
arterial circulation. Endoleak occurrence is associated with high intrasac pressures, and requires a quick repair to
prevent abdominal aortic aneurysm rupture.
Case presentation: We report the first case of a 80-year-old man undergoing percutaneous closure of a peri-graft
endoleak (type I) by transcatheter embolization through radial arterial access.
Conclusion: The transradial approach has been shown to be a safe and effective alternative to the traditional
transfemoral approach. A decrease in vascular complications and improved patient comfort are the primary
benefits of this technique in patients with previous EVAR.
Background
Peripheral arterial disease (PAD) is one of the most fre-
quent manifestations of atherosclerosis and it is asso-
ciated to a high incidence of major cardiovascular
events [1-5]; it might involve the abdominal aorta, the
epi-aortic trunks and the limb arteries [6-8]. Aortic
abdominal aneurysms (AAA) are frequent expressions of
PAD [9] and represent a frequent cause of mortality and
morbidity, particularly in men older than 60 years. AAA
particularly affect the iuxtarenal portion of the abdom-
inal aorta and are defined as an increase of the antero-
posterior diameter of the aorta of more than 3 cm [10].
Risk factors for developing an AAA are the same of
atherosclerosis, in particular the relative risk seems to
significantly increase with the number of daily smoked
cigarettes [11]. AAA are associated with a high risk of
rupture, which is frequently fatal [2,12], so it is neces-
sary to perform preventive measures to avoid such even-
tuality. Most recent guidelines suggest a threshold of 5.5
cm as anteroposterior aortic diameter to decide for clin-
ical surveillance (when inferior) or for operative mea-
sures (when superior), even though AAA with a
diameter of 5 cm may be considered for intervention in
particular cases [2,13].
The classical intervention for treating an AAA is the
surgical excission of the dilated sac and the use of a
prosthesis, generally made in Goretex, to restore the
vascular continuity; however, despite the improving in
surgical and anesthetic techniques, this complex proce-
dure still carries an high peri-operative risk [14,15].
Recently, endovascular aortic repair (EVAR) has been
proposed as an attractive alternative for selected patients
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since 1991, when Parodi et al performed the first endo-
vascular positioning of an aortic endoprosthesis excluding
the aneurysmatic dilation [16]. Although EVAR short and
mid-term results indicate that this procedure is effective
and might be even safer than classical open repair, given
to the lack of long term follow up data, it is still consid-
ered a second choice compared to classic surgery, rather
than an equal alternative [2]. Undoubtedly, EVAR down-
sides include anatomic limitations making this procedure
unsuitable in some cases (renal arteries interested into
aneurysm sac; short, angulated AAA etc), thrombotic
graft occlusions and stent migrations that might cause a
re-enlargement of the previously excluded aneurysm [12].
The most frequent complications of EVAR are intrasac
endoleaks, which may be defined as the presence of a
continuous blood flow into the excluded sac [17].
Currently, the most commonly accepted classification
for endoleaks encompasses five types, on the basis of the
origin of the anomalous flow (Table 1). Type I endoleaks
occur at either a proximal (type IA) or distal (type IB)
incompetent attachment site, and allow a persistent com-
munication between the pressure-filled aortic lumen and
the aneurysm sac or excluded portion of the aortic
lumen, producing high intrasac pressures that can lead
to rupture. Type II endoleaks are the result of retrograde
flow from branch vessels (for example, lumbar arteries
and the inferior mesenteric artery). Type III endoleaks
are due to a junctional leak between two modular seg-
ments of stent-grafts or due to a graft fabric disruption.
As type I endoleaks, they are associated with measure-
able increases in aneurysm sac size and require urgent
management. Type IV endoleaks are the result of high
graft porosity and diffuse microleakage through its inter-
stices, usually within 30 days of implantation, and are
rare compared with the frequency of other endoleaks.
Finally, the terms “type V endoleaks” and “endotension”
have been coined to those circumstances in which the
excluded sac continues to enlarge despite the absence of
any visible endoleaks on contrast-enhanced computed
tomographic scans.
The management of post-operative endoleaks depend
on the specific type, and in most cases only type I/III
require a rapid repair to prevent aneurysm rupture
[12,17]. Standard endovascular treatment options for
type IA endoleaks include the insertion of an aortic cuff
to extend endograft coverage more proximally, or the
placement of a large-caliber balloon-expandable stent
(e.g. Palmaz or Sinus) inside the proximal endograft to
promote the seal. Standard therapy for type IB endo-
leaks involves distal extension of endograft coverage.
If an endoleak persists despite these measures, definitive
therapy may require conventional open surgery, combin-
ing visceral artery bypass with stent-graft extension or
the use of chimney or periscope grafts to extend proxi-
mal and distal landing zones.
Patients who are not eligible for these more complex
procedures, because of severe co-morbidities or adverse
anatomical factors, may be treated by trans-catheter
embolization of the endoleak itself. There is limited
published experience of type I endoleak embolization
and previous reports have involved coils and n-butyl
2-cyanoacrylate (n-BCA). Onyx (ev3, Irvine, CA, USA)
is a relatively novel non-adhesive liquid embolic agent,
which is most commonly used to treat intracranial arter-
iovenous malformations. It is comprised of ethylene
vinyl alcohol dissolved in dimethyl sulphoxide (DMSO),
an organosulfur compound frequently employed into
molecular biology studies [18,19], and suspended micro-
nized tantalum powder to provide contrast for visualiza-
tion under fluoroscopy [20].
Treatment of EVAR endoleaks is generally performed
through femoral arterial access; however, radial access
are generally associated to lower costs, fewer vascular
complications and earlier ambulation. We describe a
first case of a patient undergoing percutaneous closure
of a type I peri-graft endoleak by embolization release
controlled spirals and liquid embolization Onyx through
radial arterial access.
Case presentation
An 80-year-old man, affected by coronary artery disease,
chronic obstructive pulmonary disease, arterial hyper-
tension and dyslipidemia, former heavy smoker, was
admitted to our Department on May 5, 2011. Previous
Doppler ultrasound exams had shown the presence of
an aneurysmatic dilatation of the infra-renal portion of
the aorta, which had been followed-up until reaching a
maximum diameter of almost 5.2 cm (January 2011).
Thus, the patient underwent computed tomography
(CT) angiographic imaging, which demonstrated aneur-
ysm sac shrinkage of about 5 × 5.5 cm, with a longitudi-
nal extension of about 8 cm and showed also signs of
Table 1 Endoleaks classification
Type I: Incompetent attachment site leaks
IA Proximal end of endograft
IB Distal end of endograft
IC Iliac occluder (plug)
Type II: Branch vessel leaks without attachment site connection
IIA From only 1 patent branch
IIB From 2 or more patent branches
Type III: Graft defect
IIIA Junctional leak or modular disconnect
IIIB Fabric disruption (midgraft hole)
Type IV Graft wall (fabric) porosity (<30 d after graft placement)
Type V Aneurysm sac enlargement with no detectable endoleak
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mural thrombotic apposition of about 3 cm of maxi-
mum assial thickness.
Physical examination evidenced a tender and pulsatile
abdominal mass, accompanied by the auscultatory find-
ing of a systolic murmur in the paraumbilical region.
During the hospitalization, aortic ecotomography was
repeated and revealed maximum diameters of the aneur-
ysmatic formation of about 6 × 5.8 cm, confirming the
presence of a large, eccentric intra-sac thrombus. The
patient also underwent coronary angiography, which
showed significant stenosis of the left anterior descend-
ing coronary artery and of the circumflex coronary
artery, which were judged not amenable of percutaneous
treatment. Given the size of the aneurysm sac (and, in
particular, the progressive and quick enlargement), the
presence of intramural thrombotic burden causing a not
trivial potential risk of a severe peripheral embolism and
the severe coronary artery disease, we decided to per-
form EVAR with implantation of an aorto-bisiliac endo-
prosthesis, using surgical isolation and access of the left
common femoral artery and percutaneous access of the
right common femoral artery. At the final angiographic
control, no endoleak was visible. The following hospital
course was completely devoid of complications, without
significant post-operative anemia or signs of infections,
and the patient was discharged five days after the
procedure.
In July 2012, a routine CT control revealed the pre-
sence of an apparent type I endoleak. The patient was
in a clinically stable state (without any symptoms and
no signs of anemia). Aortography confirmed the
presence of a posterior peri-graft large leak (Figure 1A).
The patient declined the high-risk option of open
surgical repair in favor of a final endovascular attempt.
He underwent percutaneous closure of the peri-graft
endoleak (type I) by means of embolization release con-
trolled spirals and liquid embolization Onyx. Trans-
arterial embolization was performed via the radial artery
approach. A right radial access was obtained using a
micro-puncture kit (Cook Medical), and a 6 Fr sheath
(Cordis) was placed in the right radial artery without
difficulty. The endoleak channel was engaged with a
(SOS Omni) selective catheter. The presence and loca-
tion of the type I endoleak was confirmed by aortogra-
phy. The aneurysm sac was treated using embolization
release controlled spirals and liquid embolization Onyx
(Micro Therapeutics Iac, Irvine, Calif) (Figure 1B).
Before injection of Onyx, the microcatheter was flushed
with DMSO and Onyx was subsequently injected under
fluoroscopy. We used the currently available solutions
Onyx-18 (6 % Ethylene vinyl alcohol (EVOH)/94 %
DMSO), Onyx-20 (6.5 % EVOH/93.5 % DMSO) or
Onyx-34 (8 % EVOH/92 % DMSO). Onyx-18 had the low-
est and Onyx-34 the highest viscosity. Post-embolization
angiography showed no further endoleak (Figure 1C). At
3-month-follow-up, the patient was free of radiographic
evidence of type I endoleak or aneurysm sac espansion.
Conclusions
Endovascular treatment of aortic aneurysms has pro-
gressively improved and has widely replaced the classi-
cal surgical procedures [6-8,21-24]. EVAR is widely
Figure 1 A. Angiogram following placement of aortic endograft shows a type I endoleak. B. Closure of perigraft endoleak by means
of embolization release controlled spirals and liquid embolization Onyx. C. Angiogram showing resolution of Type I endoleak.
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accepted as a safer and less invasive alternative to open
repair. The most common complication of EVAR is
endoleak, which occurs when the aortic sac continues to
be perfused despite graft fixation. Type I endoleaks are
the most frequent and occur at either proximal or distal
attachment site or landing zone. These leaks are conse-
quence of a failing apposition of the stent-graft to the
cylindrical aortic wall within the landing zone allowing a
persistent communication between the pressure-filled
aortic lumen and the aneurysm sac or excluded portion
of the aortic lumen. The EUROSTAR investigators have
also demonstrated that endoleak type I is significantly
associated with rupture risk after EVAR [25]. Endovas-
cular technique has significantly decreased mortality
rate when compared to open surgery. Endovascular
treatment of type I endoleaks requires a complete flow
elimination to exclude the aneurysm sac from systemic
pressure.
The transradial approach appears to be a safe and
effective alternative to the traditional transfemoral
approach. The primay benefits of this technique, when
compared to femoral artery access, are a decrease in vas-
cular complications, improved patient comfort, earlier
ambulation and lower direct costs. Asymptomatic radial
artery occlusion, non-occlusive radial artery injury and
radial artery spasm are commonly reported complications
[26,27]. Symptomatic radial arterial occlusion, pseudoa-
neurysm and radial artery perforation are much less com-
mon. The risk of arterial perforation with the transradial
approach is less than 1%, primarily involving the radial
artery with the incidence of compartment syndrome at
approximately 0.004% [28]. In addition, the risk of signifi-
cant bleeding requiring transfusion with the transradial
approach is extremely rare, occurring in about one
patient in a thousand [29].
In this report, we present a case of successful endovas-
cular treatment of type I endoleak by embolization release
controlled spirals and liquid embolization Onyx. For
trans-arterial embolization, many authors reported the use
of microcoils or n-BCA as embolizing materials, but Onyx
has shown safety advantages [30]. Onyx is an ethylene
vinyl alcohol copolymer dissolved in various concentra-
tions of DMSO and opacified with micronized Tantalum
powder for X-ray visualization. When this mixture con-
tacts blood, DMSO diffuses away resulting in solidification
of the polymer [31]. Disadvantages of the use of Onyx for
endoleak treatment are its high radio-opacity on follow-up
CT scans (causing a difficult detection of small persistent
endoleaks, comparable to artifacts with coils after endoleak
embolization and image subtraction), a relatively long (20
minutes) preparation time, the potential for vasospasm
and the high costs [32,33]. Embolization is considered
clinically successful when the volume of the aneurysm sac
is stable or decreased at follow-up CT scans.
In conclusion, endoleaks remain the primary limita-
tion of endovascular stent-grafting of the abdominal
aorta. Type I endoleak is associated with a significantly
greater risk of rupture of the aneurysm. Many patients
will be able to benefit from endovascular treatment
approach to aortic disease through radial arterial access.
Larger patient numbers and longer-term follow-up are
needed to define procedural efficacy and durability.
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